SLS-009, an allele-specific gene therapy, reduces mHTT aggregates in Huntington’s disease mice

June 6, 2023

Researchers from Seelos Therapeutics Inc. presented the discovery and preclinical evaluation of a gene therapy candidate, SLS-009, for the treatment of Huntington’s disease (HD).

BioWorld Science Conferences Neurology/Psychiatric Gene therapy

Today's news in brief

BioWorld

BioWorld briefs for Sept. 21, 2023.

Myelin damaged by multiple sclerosis could be repaired by reducing levels of an enzyme

BioWorld Science

In multiple sclerosis (MS), macrophages and microglia play a dual role that could be used to treat this neurodegenerative disease. These cells promote...

Today's news in brief

BioWorld MedTech

BioWorld MedTech briefs for September 21, 2023.

Quite a fix: Orthofix sacks three top execs

BioWorld MedTech

Orthofix Medical Inc. terminated its CEO, chief financial officer and chief legal officer in a move that plunged the stock from $18.63 at Monday’s close to $13.01...

Challenges in China spell trouble for Illumina, 10x and others

BioWorld MedTech

China’s recovery from its zero-COVID policy has failed to gain the momentum expected, with many experts predicting a slow or even negative growth rate. A slower...

Upgrade your daily dose of biopharma and medtech news

SLS-009, an allele-specific gene therapy, reduces mHTT aggregates in Huntington’s disease mice